Disclosed is a use of a CD20 antibody in the manufacture of a medicament for use in treating multiple sclerosis in a subject wherein the medicament is administered and/or is formulated to provide an initial antibody exposure of about 0.5 to 4 grams followed by a second antibody exposure of about 0.5 to 4 grams, the second exposure not being provided until from about 16 to 60 weeks from the initial exposure, and each of the antibody exposures is provided to the subject as one or two doses of antibody, and wherein the antibody is a humanised CD20 antibody comprising a light chain comprising a CDR L1 having the amino acid sequence RASSSVSYMH, a CDR L2 having the amino acid sequence APSNLAS, and a CDR L3 having the amino acid sequence QQWSFNPPT, and a heavy chain comprising a CDR H1 having the amino acid sequence GYTFTSYNMH, a CDR H2 having the amino acid sequence AIYPGNGDTSYNQKFKG, and a CDR H3 having the amino acid sequence VVYYSNSYWYFDV.
